JMP reiterates Acadia at market outperform

Acadia Pharmaceuticals Inc. was given a market outperform rating by JMP Securities analyst Charles C. Duncan. The analyst raised the price target to $18 from $15. The significant clinical data expected in the first quarter from ACP-103 in Parkinson's disease, if positive, could signal activity in other neuropsychiatric indications, JMP believes. Shares of the San Diego biopharmaceutical company were down 31 cents, or 2.01%, at $15.12 on volume of 505,107 shares versus the three-month running average of 376,795 shares. (Nasdaq: ACAD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.